StockData
Integra LifeSciences Holdings Corp logo

Integra LifeSciences Holdings Corp (IART) company profile

IARTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 23, 2026Score 9/308% below fair value
$13.55−0.43 (-3.08%)

Close on Nov 17, 2026Market cap $1.05BP/E 79.7Yield –

About Integra LifeSciences

Surgical & Medical Instruments & Apparatus, SIC 3841

Integra LifeSciences Holdings Corporation manufactures and sells medical technologies across two main business segments: Codman Specialty Surgical and Tissue Technologies. The specialty surgical segment supplies neurosurgical devices, neuro-monitoring systems, cranial stabilization equipment, ultrasonic tissue ablation tools, surgical headlamps, and specialty handheld instruments. The tissue technologies segment provides regenerative biomaterials, collagen implants, porcine matrices, human placental allografts, and dressings for wound management, plastic reconstruction, and general surgery. The company also produces private-label products for other medical firms. Its customers include hospitals, outpatient surgery centers, wound clinics, integrated health networks, and medical practices.

The enterprise markets products worldwide through direct sales representatives and independent distributors, serving markets in North America, Europe, and Asia, including China, Japan, South Korea, India, and Brazil. It maintains manufacturing and research facilities in eight U.S. states and Puerto Rico, as well as in France, Germany, Ireland, Israel, and Switzerland, plus an assembly site in Suzhou, China. The excerpt does not disclose the company's headquarters location.

Summary of the business section of Integra LifeSciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Integra LifeSciences Holdings Corp
Founded
1989
Headquarters
Princeton, NJ
Address
1100 Campus Road 08540
Phone
(609) 275-0500
Employees
3,700, Dec 31, 2020
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Florham Park, New Jersey

Stock & identifiers

Ticker
IART
Exchange
Nasdaq
IPO date
Aug 16, 1995
Shares outstanding
78M, Oct 22, 2026
Public float
$925.10M, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
2-for-1, Jan 4, 2017; 1-for-2 reverse, May 26, 1998
SEC CIK
917520
CUSIP
457985208
ISIN
US4579852082
FIGI
BBG000BZJQL8
Share class FIGI
BBG001S7JWM6
LEI
WB7IJCYY8YFTENS4O147
EIN
51-0317849

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Stuart EssigPresident and CEO, Director1,785,271
Mojdeh PoulPresident & CEO, Director0
Andrea B. CarusoCVP & CHRO43,590
Lesha R. ShinnCVP, Chief Legal Officer & Sec26,838
Chantal Veillon-BertelootEVP & CHRO20,772
Jeffrey MosebrookSVP, Fin & Princ Acct Officer34,516
Harvinder SinghEVP & President, SS40,612
Robert T. Davis Jr.EVP & President, TR&DT66,387
Lea Daniels KnightEVP & Chief Financial Officer45,263
Michael J. McBreenEVP & Chief Commercial Officer60,743
Michael Damon HutchinsonEVP, Chief Legal Officer & Sec–
Eric SchwartzEVP, Chief Legal Officer & Sec56,020
Christian S. SchadeDirector90,034
Barbara B. HillDirector187,541
Shaundra ClayDirector41,515
Renee Wonlai LoDirector35,743
Jeffrey A. GravesDirector41,086
Keith BradleyDirector88,254

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Jan De Witte
$282.68K-$1.26M$2.28M$19$123
FY2025
Mojdeh Poul
$9.38M$4.26M$2.28M$19$123
FY2024
De Witte
$7.49M-$217.84K$2.80M$39$138
FY2024
Jan De Witte
$7.49M-$217.84K$2.80M$39$138
FY2023
De Witte
$6.39M$3.05M$1.76M$75$138
FY2023
Jan De Witte
$6.39M$3.05M$1.76M$75$138

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Mojdeh Poul
President and Chief Executive Officer and Director
$1.01M$350.44K$5.22M$2.25M$174.56K$371.06K$9.38M–
Lea Knight
Executive Vice President and Chief Financial Officer
$638.65K$154.90K$1.50M$499.57K$77.16K$14.00K$2.88M-8%
Robert T. Davis, Jr
Executive Vice President, President, Tissue Technologies
$583.35K$69.59K$892.71K$297.57K$55.41K$14.00K$1.91M-15%
Michael J. McBreen
Executive Vice President, President, Codman Specialty Surgical
$643.75K$212.41K$1.33M$442.58K$72.78K$14.00K$2.71M-14%
Harvinder Singh
Executive Vice President, President, International
$563.99K$91.19K$683.13K$227.70K$45.43K$14.00K$1.63M-38%
Jan De Witte
Former President and Chief Executive Officer and Director
$42.31K––––$240.37K$282.68K-96%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2020, we had approximately 3,700 full-time and part-time employees and 700 contingent, subcontracted and outsourced partners.”

Corporate history

Events identified from SEC filings

DateEventDetails
May 9, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 18, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 2, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 24, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 28, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 2, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 3, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 20, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 8, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 9, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 27, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 2, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 15, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 26, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 3, 2009Late filingNotification of late filing
Oct 17, 2008Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 4, 2008Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 23, 2008Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 13, 2008Late filingNotification of late filing
Mar 24, 2008Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 29, 2008Late filingNotification of late filing
Jan 14, 2008Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 30, 2007Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 10, 2007Late filingNotification of late filing
Mar 2, 2007Late filingNotification of late filing
Jul 28, 2006Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 17, 2006Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 8, 2006Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 3, 2005Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 31, 1999Name changeName changed from INTEGRA LIFESCIENCES CORP to Integra LifeSciences Holdings Corp

See a number that looks wrong?